BMT-06: Study of Intensity Modulated Total Marrow Irradiation (IM-TMI)

Phase 2 Recruiting 27 enrolled University of Illinois at Chicago

NaSingle-groupOpen-labelTreatment

Summary

This study is being done to see if the addition of a targeted form of radiation to standard conditioning regimen will increase the amount of cancer cells that are killed off in the bone marrow and reduce the chances that your disease may return. This description is called Intensity Modulated Total Marrow Irradiation (IM-TMI).

Timeline

Start: 2020-01-27
Primary completion: 2026-12
Completion: 2026-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Background	2-MERCAPTOETHANESULFONIC ACID	Small molecule	10 mg/kg	Intravenous
Background	2-MERCAPTOETHANESULFONIC ACID	Small molecule	14.5 mg/kg	Intravenous
Background	Cyclophosphamide	Other / unclassified	14.5 mg/kg	Intravenous
Background	Cyclophosphamide	Other / unclassified	50 mg/kg	Intravenous
Background	Fludarabine	Small molecule	30 mg/m2	Intravenous
Background	Mycophenolate Mofetil	Small molecule	15 mg/kg	Oral
Background	Tacrolimus	Small molecule	0.03 mg/kg	—

BMT-06: Study of Intensity Modulated Total Marrow Irradiation (IM-TMI)

Summary

Timeline

Drugs

Indications